← FDA DRUG APPROVALS

FDA NDA · NDA217470

OPVEE

nalmefene hydrochloride

Sponsor: INDIVIOR

APPLICATION
NDA217470
TYPE
NDA
ORIGINAL APPROVAL
2023-05-22
LATEST ACTION
2023-05-22
ROUTE
NASAL
DOSAGE FORM
SPRAY
MARKETING STATUS
Prescription

Products

OPVEE · ReferencePrescription
NALMEFENE HYDROCHLORIDE EQ 2.7MG BASE/SPRAY · SPRAY · NASAL

Approval history

2023-05-22Type 3 - New Dosage Form · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →